Galera Therapeutics Business Summary

Galera Therapeutics, Inc. (GRTX) is a clinical-stage biopharmaceutical company that generates revenue through a hybrid model of non-dilutive funding, including National Institutes of Health (NIH) grants, and strategic asset monetization. Following a significant pivot in late 2024 and 2025, the company sold its legacy dismutase mimetics portfolio to Biossil Inc. for up to $105 million in milestone-based payments while acquiring Nova Pharmaceuticals to focus on its primary business segment: the development of pan-NOS inhibitors for refractory oncology indications. Its lead program, L-NMMA (tilarginine), is currently in Phase 1/2 clinical trials targeting high-unmet-need areas such as metaplastic breast cancer (MpBC) and triple-negative breast cancer (TNBC). Galera operates as a micro-cap entity within the over-the-counter (OTCQB) market, positioning itself as a high-risk, lean-operation developer of niche cancer therapies. It competes directly with other clinical-stage biotech firms such as Altimmune, Euclises, and Adastra Pharmaceuticals, distinguishing itself through its specific focus on the nitric oxide synthase pathway to overcome chemotherapy resistance. The company was founded in 2009 by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley. Current leadership is headed by J. Mel Sorensen, M.D., who serves as President, CEO, and Chairman of the Board; Dr. Sorensen is a medical oncologist with an M.B., B.Ch. from University College Dublin and extensive experience in clinical development at companies like GlaxoSmithKline and Bayer. Supporting him is Joel Sussman, CPA, who serves as Chief Accounting Officer, alongside key functional leaders Andie Collier (Regulatory and Quality) and Judy Fox, Ph.D. (Drug Development). The Board of Directors was reconstituted following the Nova Pharmaceuticals acquisition to include industry veterans such as Dr. Nancy T. Chang, a renowned biochemist and co-founder of Tanox, and Michael Friedman, an investment banking expert. This leadership team is currently focused on executing a cost-rationalization strategy to extend the company's cash runway through critical data readouts in 2026.